Diagnostics Pipeline: Startup Women’s Health Lab Receives $4M in Federal Grants
The grants, which include $3 million from the NIH and $1 million from the NSF, will help the company develop point-of-care tests
Keeps You Up-to-Date on New Diagnostic Tests, Testing Trends and Opportunities, and Emerging Test Technologies
The grants, which include $3 million from the NIH and $1 million from the NSF, will help the company develop point-of-care tests
September was an eventful month for one of the hottest products on the consumer genetic test market, the Cologuard multi-target stool DNA test (mtSDNA) for colorectal cancer screening produced by Exact Sciences. The month started badly with the release of a CMS-sponsored research report finding Cologuard “less effective and considerably more costly” than alternatives. Although Exact Sciences quickly criticized the report and its analytical methodology, its stock took a beating.